ClinicalTrials.gg
Not yet recruitingNCT06935552Updated Apr 20, 2025

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine

An Early Phase 1 interventional study of Ketamine infusion and Lidocaine Intravenous Infusion in Refractory Chronic Migraine, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Assiut University · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing lidocaine in Migraine Disorders — 5 open to participants now, 5 under way, none of them phase 3. Lidocaine · Migraine Disorders.

Planned enrollment
9th of 13
44 · median 50
Started
2025
with 2 others
Phase 1
2 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Assiut University

Among the 13 studies testing lidocaine in Migraine Disorders, this one is the 9th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 9th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

5 of the 13 studies testing lidocaine in Migraine Disorders are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lidocaine in Migraine Disorders, or all of them as a file.
02

Study summary

Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study

03

Conditions studied

  • Refractory Chronic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must fulfill the following inclusion criteria

    1. medically stable outpatients with confirmed diagnosis of chronic migraine according to American Headache society
    2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow up.
    3. Men or women older than 18years of age.
    4. clear written from each participant in the trial.
    5. Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities
  2. presence of medical or psychiatric condition that may increase the risk associated with the study
  3. participation in any other type of medical research that may interfere with the interpretation of the study.
  4. patients with hemocoagulation disorders, local infection or those who refused to consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Ketamine

    will receive ketamine

    Drug: Ketamine infusion

  • Experimental
    Lidocaine

    will receive lidocaine

    Drug: Lidocaine Intravenous Infusion

  • Placebo comparator
    Dextrose

    Drug: Dextrose 5% in water

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    group A will receive ketamine intravenous infusion

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    group B will receive lidocaine intravenous infusion

  • DrugDextrose 5% in water

    group C will only receive Dextrose 5% in water

06

What researchers measure

Primary outcomes

  1. Changes in pain scale using Numeric rating scale

    Pain assessment by using a Numeric rating scale (0 (no pain) to 10 (worst possible pain). Scores of 1-3 are considered mild, 4-6 moderate, and 7-10 severe) before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion

    Time frame: From enrollment to the end of treatment at 6 weeks

  2. Changes in pain scale using Migraine disability assessment

    Migraine disability assessment test before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion

    Time frame: From enrollment to the end of treatment at 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 Jun;48(6):778-82. doi: 10.1111/j.1526-4610.2008.01132.x. Epub 2008 May 14. PubMed 18484982 ↗
  • Ray JC, Cheng S, Tsan K, Hussain H, Stark RJ, Matharu MS, Hutton E. Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study. Front Neurol. 2022 Mar 9;13:842082. doi: 10.3389/fneur.2022.842082. eCollection 2022. PubMed 35356451 ↗
  • Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6. doi: 10.1590/s0034-70942008000300011. English, Portuguese. PubMed 19378524 ↗
  • Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186-93. doi: 10.1097/00000539-199811000-00039. No abstract available. PubMed 9806706 ↗
  • Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599-609. doi: 10.1111/j.1468-2982.2009.01941.x. PubMed 19614702 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Nov 2026, 17 months later.

Of 53 phase 1 interventional studies under Migraine Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 20, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06935552
Lead sponsor
Assiut University
Responsible party
AbdElRahman Mohamed Mohamed Mohamed (Resident doctor in neurology and psychiatry department, Assiut University) — Principal investigator
First posted
Apr 20, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 20, 2025

Study contacts

AbdElRahman Mohamed Mohamed
Contact
hmdmhmmdl1692@gmail.com
+201066586931
Nageh Fouly Kamel, PhD.
study chair · Assiut University
Mohamed Ahmed Abdelhameed, PhD.
study chair · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Lidocaine

Start the discussion